These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 9723237)
1. Early cyclosporine blood levels impact the incidence of acute rejection and overall mortality in the first year after heart transplantation. Gómez-Sánchez MA; Delgado JF; Escribano P; Santos M; Sotelo T; Gil R; Hernández-Afonso J; Ortuño B; Romero F; Sáenz de la Calzada C; Rodriguez JE; Rufilanchas JJ Transplant Proc; 1998 Aug; 30(5):1671-2. PubMed ID: 9723237 [No Abstract] [Full Text] [Related]
2. Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience. Adamson R; Obispo E; Dychter S; Dembitsky W; Moreno-Cabral R; Jaski B; Gordon J; Hoagland P; Moore K; King J; Andrews J; Rich M; Daily PO Transplant Proc; 1998 Jun; 30(4):1107-9. PubMed ID: 9636449 [No Abstract] [Full Text] [Related]
3. Lower incidence of liver graft rejection in patients on diltiazem plus cyclosporine therapy. Mies S; Massarollo PC; Figueira ER; Leitão RM; Raia S Transplant Proc; 1998 Jun; 30(4):1437-8. PubMed ID: 9636582 [No Abstract] [Full Text] [Related]
4. Induction of immunosuppression with OKT3 following heart transplantation: kidney function as a criterion for control of protocol duration. Rodríguez JA; Crespo-Leiro MG; Paniagua MJ; Muñiz J; Hermida LF; Fojón S; Cuenca JJ; Juffé-Stein A; Castro-Beiras A Transplant Proc; 1999 Sep; 31(6):2517-8. PubMed ID: 10500696 [No Abstract] [Full Text] [Related]
5. Limited utility of early trough cyclosporine level monitoring to predict the rate of acute rejection in the first three months after cardiac transplantation. Jennison SH; Wesp AG; McBride LR; Miller LW Transplant Proc; 1994 Oct; 26(5):2732-5. PubMed ID: 7940857 [No Abstract] [Full Text] [Related]
6. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients. Hanrahan JS; Ibrahim H; Tolman D; Kirchberg D; Salter D; Guerraty A; Mohanty PK Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168 [No Abstract] [Full Text] [Related]
7. Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction. Cantarovich M; Quantz M; Elstein E; Ergina P; Magnan C; de Varennes B Transplant Proc; 2000 Mar; 32(2):446-8. PubMed ID: 10715475 [No Abstract] [Full Text] [Related]
8. Effects of cyclosporine A monotherapy on the incidence of rejection and infection episodes in heart transplant patients. Seydoux C; Stumpe F; Hurni M; Ruchat P; Fischer A; Mueller X; von Segesser L; Goy JJ Transplant Proc; 1998 Dec; 30(8):4037-43. PubMed ID: 9865288 [No Abstract] [Full Text] [Related]
9. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients. Marcus N; Khaghani A; Burke M; Yacoub M; Banner N Transplant Proc; 1998 Jun; 30(4):1134-5. PubMed ID: 9636460 [No Abstract] [Full Text] [Related]